Clinical Trials was Cannabis Bioscience International Holdings’s largest product and service line in fiscal 2025, bringing in $301.73K of $303.02K (100%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Clinical Trials | $267.22K | $213.87K | $301.73K |
| Consulting Fees | $8.33K | $28.64K | — |
| Merchandise | $22.30K | $4.41K | $1.29K |
| Seminar Fees | $16.43K | $1.93K | — |
| Video Course | $2.50K | — | — |
| Royalty | $42 | — | — |
| Total | $316.83K | $248.84K | $303.02K |
Cannabis Bioscience International Holdings brought in $303.02K from its two product and service lines in fiscal 2025, the year ended May 31, 2025. Cannabis Bioscience International Holdings regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $248.84K. Clinical Trials was the largest at $301.73K (99.6%), ahead of Merchandise at $1.29K (0.4%).
Cannabis Bioscience International Holdings stopped reporting Consulting Fees ($28.64K in fiscal 2024), Video Course ($2.50K in fiscal 2023), Seminar Fees ($1.93K in fiscal 2024) and one other as separate lines.
Cannabis Bioscience International Holdings (CBIH) reports its revenue by product and service. In fiscal 2025, Clinical Trials was its largest product and service line, bringing in $301.73K (99.6% of the total), followed by Merchandise at $1.29K (0.4%).
Clinical Trials was Cannabis Bioscience International Holdings' largest product and service line in fiscal 2025, bringing in $301.73K, or 99.6% of the $303.02K total across its two product and service lines.
Every figure comes from Cannabis Bioscience International Holdings' annual financial filings, as reported. Each line keeps the name Cannabis Bioscience International Holdings gives it, and years follow its fiscal calendar.
Cannabis Bioscience International Holdings' revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.